Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Combination of PI3K and MEK inhibitors yields durable remission in PDX models of PIK3CA-mutated metaplastic breast cancers.

Journal of hematology & oncology - 22 Feb 2020

Coussy F, El Botty R, Lavigne M, Gu C, Fuhrmann L, Briaux A, de Koning L, Dahmani A, Montaudon E, Morisset L, Huguet L, Sourd L, Painsec P, Chateau-Joubert S, Larcher T, Vacher S, Melaabi S, Salomon A Vincent, Marangoni E, Bieche I

Abstract excerpt

BACKGROUND: Metaplastic breast cancer (MBC) is a rare form of breast cancer characterized by an aggressive clinical presentation, with a poor response to standard chemotherapy. MBCs are typically triple-negative breast cancers (TNBCs), frequently with alterations to genes of the PI3K-AKT-mTOR and RTK-MAPK signaling pathways. The objective of this study was to determine the response to PI3K and MAPK pathway...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Class I Phosphatidylinositol 3-Kinases
Share to Mice, Nude

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mitogen-Activated Protein Kinase Kinases

Share to Phosphoinositide-3 Kinase Inhibitors

Share to Proto-Oncogene Proteins c-akt

Share to TOR Serine-Threonine Kinases

Share to Triple Negative Breast Neoplasms

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 32087759
DOI: 10.1186/s13045-020-0846-y
PMCID: PMC7036180

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Combination of PI3K and MEK inhibitors yields durable remission in PDX models of PIK3CA-mutated metaplastic breast cancers.PMID 32087759Read ↗

The Landscape of Somatic Genetic Alterations in Metaplastic Breast Carcinomas.Semantic proximity Read ↗

A large collection of integrated genomically characterized patient‐derived xenografts highlighting the heterogeneity of triple‐negative breast cancerSemantic proximity Read ↗

A comprehensive overview of metaplastic breast cancer: Features and treatments.Semantic proximity Read ↗

Patient-derived xenografts of triple-negative breast cancer reproduce molecular features of patient tumors and respond to mTOR inhibition.Semantic proximity Read ↗

Mutation and immune profiling of metaplastic breast cancer: Correlation with survival.Semantic proximity Read ↗

Response to mTOR and PI3K inhibitors in enzalutamide-resistant luminal androgen receptor triple-negative breast cancer patient-derived xenografts.Semantic proximity Read ↗

Mutational Landscape of PI3K-AKT-mTOR Pathway in Breast Cancer: Implications for Targeted TherapeuticsSemantic proximity Read ↗

Genomic characterization and tumor evolution in paired samples of metaplastic breast carcinoma.Semantic proximity Read ↗

Phenotypic and molecular dissection of metaplastic breast cancer and the prognostic implicationsSemantic proximity Read ↗

Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a review.Semantic proximity Read ↗

Spectrum of PIK3CA/AKT mutations across molecular subtypes of triple-negative breast cancer.Semantic proximity Read ↗

The Correlation of PD-L1 Expression in Metaplastic BreastCancers with Clinical-Pathological Features and PrognosisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.